Posted on

Novamind Announces Strategic Investment in the Synthesis Institute, a Renowned Legal Psilocybin Retreat in the Netherlands

TORONTO, Ontario – November 18, 2019 – Novamind Ventures Inc. (“Novamind”) is pleased to announce that it has committed to lead the Synthesis Institute B.V.’s (“Synthesis”) Seed Financing, with a strategic investment of €750,000.  Following the close of the investment, Yaron Conforti, Chief Executive Officer of Novamind will join Synthesis’ Board of Directors.

Synthesis is an industry-leading, legal psilocybin retreat center in the Netherlands. Since its inception in 2018, Synthesis has had over 450 participants in its multi-day retreats and has curated an expert team of facilitators, therapists, meditation and breathwork instructors. Synthesis has created an experience that blends the best of ancient practices with modern research for individuals who want to catalyze creative breakthroughs and explore their consciousness.

Before a participant is accepted into one of Synthesis’ programs, they undergo prerequisite health screening to ensure their suitability and safety. Synthesis’ retreats are hosted at a private location 30 minutes from Amsterdam at a venue offering an optimal setting for transformative psychedelic experiences.

Through its investment in Synthesis, Novamind supports the development of psychedelic-assisted psychotherapy protocols, patient screening tools and leading facilitators. Novamind is evaluating a pipeline of early-stage investment opportunities in the psychedelic space and expects to make additional announcements in due course.

About the Synthesis Institute B.V.

Synthesis offers legal, medically supervised psychedelic retreats in the Netherlands. Founded in 2018, it makes psilocybin experiences accessible for curious individuals who want to catalyze creative breakthroughs, explore consciousness, find meaning, improve confidence and search for a mystical experience. For more information visit www.synthesisretreat.com.

About Novamind

Novamind invests in the infrastructure that drives the world’s leading psychedelic clinics and retreats.  We seek to accelerate research and innovation in psychedelic medicine by investing in the people, science and technology required for a regulated psychedelics industry. Novamind is building a new standard of mental healthcare. For more information visit www.novamind.ca.

Contact Information

Yaron Conforti, CEO
T: +1 (647) 953 9512
E: info@novamind.ca

Posted on

Novamind Commits Initial Funding to Facilitate Safe, Legal Psychedelic Experiences

TORONTO, Ontario – November 15, 2019 – Novamind Ventures Inc. (”Novamind”) is pleased to announce that it has closed its seed financing round (the “Seed Round”) with a total investment of CAN$907,500. The Seed Round was led by Novamind’s founders and included participation from a limited group of investors.

Novamind is an investment and operating company focused on building the infrastructure required to facilitate safe, legal psychedelic experiences at the world’s leading psychedelic clinics and retreats.

MDMA and psilocybin, targeted as treatments for PTSD and depression respectively, are in late-stage clinical trials approved by the U.S. Food and Drug Administration (“FDA”) and are demonstrating encouraging results showing successful outcomes for patients with treatment-resistant conditions.

Based on the expected success of the FDA clinical trials for psychedelic medicines, Novamind anticipates a regulated psychedelics industry that will require specialized infrastructure to facilitate patient treatment. Novamind invests in the infrastructure, protocols, and people that are required for a regulated psychedelics industry.

Background

In 2017, the FDA granted a Breakthrough Therapy Designation for MDMA-assisted psychotherapy for the treatment of PTSD, with the associated clinical trial now in Phase III.  In 2018 and 2019, the FDA also granted a Breakthrough Therapy Designations to psilocybin-assisted psychotherapy for treatment-resistant depression and major depressive disorder, with the associated clinical trials in Phase IIB and Phase II, respectively. Breakthrough Therapy Designations are intended to expedite the development and review of drugs for serious or life-threatening conditions.

Early-stage clinical research suggests that psychedelics may help treat other indications including opioid use disorder, eating disorders, nicotine use disorder and anxiety. Pending the successful outcome of these clinical trials, it is expected that regulators will require that MDMA and psilocybin treatments are administered by trained practitioners adhering to strict risk evaluation and mitigation strategies (REMS).

Novamind’s Strategy

Until such time that the FDA approves psychedelic medicines, Novamind will invest and operate exclusively in those jurisdictions with established legal regulations for the use of psychedelics.  At this time Novamind is conducting advanced due diligence on a pipeline of investment opportunities with a focus on psilocybin retreats in the Netherlands and ketamine-assisted psychotherapy clinics in the United States. Psilocybin truffles are considered legal in the Netherlands due to their omission from the Dutch Opium Act (Opiumwet) and ketamine is commonly prescribed off-label for conditions including treatment-resistant depression.

There is significant clinical data supporting the efficacy of psilocybin and ketamine-assisted psychotherapy for treatment-resistant conditions.  Novamind will invest in the infrastructure that will provide the public with access to these treatments, fostering a new standard of care.

About Novamind

Novamind invests in the infrastructure that drives the world’s leading psychedelic clinics and retreats.  We seek to accelerate research and innovation in psychedelic medicine by investing in the people, science and technology required for a regulated psychedelics industry. Novamind is building a new standard of mental healthcare. For more information visit www.novamind.ca.

Contact Information

Yaron Conforti, CEO
T: +1 (647) 953 9512
E: info@novamind.ca

Posted on

Vireo Health Names Shaun Nugent Chief Financial Officer

Nugent Brings 25 Years of Financial Experience Having Previously Served as CFO at Life Time Fitness, Champps Entertainment, and Sun Country Airlines

 

MINNEAPOLIS, Nov. 14, 2019 /PRNewswire/ — Vireo Health International, Inc. (“Vireo” or the “Company”) (CNSX: VREO; OTCQX: VREOF), the leading science-focused multi-state cannabis company, today announced that Shaun Nugent will be joining as Chief Financial Officer (“CFO”) on December 2, 2019. As CFO, Mr. Nugent will work closely with Chief Executive Officer (“CEO”) & Founder Kyle Kingsley, MD and Bruce Linton, Executive Chairman to optimize profitable growth, capital markets, and operating efficiencies.

Vireo Logo (PRNewsfoto/Vireo Health, Inc.)

Mr. Nugent has previously served as the CEO and CFO of several major private and public companies, including Life Time Fitness, AllOver Media, Champps Entertainment, and Sun Country Airlines. He is an accomplished finance executive with over 25 years of executive management experience and has raised and deployed more than US$1 billion of capital throughout his career.

Nugent’s financial leadership experience extends across multiple industries. In 2014, he was named ‘CFO of the Year’ by Twin Cities Business in recognition of his many accomplishments, which include doubling a media company’s revenue and enhancing EBITDA by 30%, scaling a national fitness firm’s revenues from less than $10M to over $200M with associated EBITDA in excess of $50M, and transforming a regional airline with one old aircraft into a profitable international commercial carrier with over $350M in annual revenue.

“Shaun’s strong track-record of increasing revenue, margin, and EBITDA in hyper-growth and capital-constrained environments is very impressive,” said CEO Kyle Kingsley, M.D. “We are excited to welcome Shaun to the Vireo family and are confident that he will help us continue to scale our business and become an even more efficient operator.”

“I can’t imagine joining a more exciting company at a more exciting time,” said Shaun Nugent. “I look forward to working closely with the entire executive team and share in the Company’s commitment to becoming a top US cannabis producer and distributor of high-margin, proprietary products and creating unprecedented long-term shareholder value.”

Mr. Nugent is a Certified Public Account (Inactive) and a graduate of the University of Wisconsin with a B.A. in Accounting.

The Company’s current CFO, Amber Shimpa, will be assuming a newly created role of Chief Administrative Officer. Ms. Shimpa will continue to serve on Vireo’s Board of Directors and as a member of the Nominating and Governance Committee.

About Vireo Health International, Inc.
Vireo Health International, Inc.’s mission is to build the cannabis company of the future by bringing the best of medicine, engineering and science to the cannabis industry.  Vireo’s physician-led team of more than 400 employees provides best-in-class cannabis products and customer experience. Vireo cultivates cannabis in environmentally friendly greenhouses, manufactures pharmaceutical-grade cannabis extracts, and sells its products at both company-owned and third-party dispensaries. The Company currently is licensed in eleven markets including Arizona, Maryland, Massachusetts, Minnesota, New Mexico, New York, Nevada, Ohio, Pennsylvania, Puerto Rico, and Rhode Island.  For more information about the Company, please visit www.vireohealth.com.

Contact Information

Media Inquiries
Albe Zakes
Vice President, Corporate Communications
albezakes@vireohealth.com
(267) 221-4800

Investor Inquiries
Sam Gibbons
Vice President, Investor Relations
samgibbons@vireohealth.com
(612) 314-8995

 

CisionView original content to download multimedia:http://www.prnewswire.com/news-releases/vireo-health-names-shaun-nugent-chief-financial-officer-300958026.html

SOURCE Vireo Health International, Inc.

Posted on

Vireo Health Appoints Amber Shimpa to the New Role of Chief Administrative Officer

VIEW ALL NEWS

Posted on

Wuhan to Launch CBD Cosmetics and CBD Infused Coffee in South Africa

Montreal, Nov. 07, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Wuhan General Group, Inc. (OTC PINK: WUHN) (the “Company” and “Wuhan”), is pleased to announce the following corporate updates:

Product Launch

The Company is delighted to announce the launching of its premium CBD product lines in the coming weeks. The launch includes the CBD cosmetics line and the CBD coffee line in pharmacies, convenience stores and hotels across South Africa. The products are branded under the trademarks: DrAnnaRx™ and Medspresso™ respectively.

Initial Creations 

  1.  CBD Advanced Revitalizing Day Cream
  2.  CBD Regenerative Night Cream
  3.  CBD Rejuvenating Skin Oil
  4.  CBD Oil Tinctures
  5.  CBD Infused Tanzanian Peaberry Coffee

Our Premium Pharmaceutical Grade CBD is supplied by Folium Bioscience using their patent-pending cannabinoid extraction technology that offers superior high bioavailability of Broad-Spectrum Phytocannabinoids. This results in a final product that is completely free of THC and ensures our customers receive the highest-quality CBD in the industry.

“Many CBD products introduced to the market are of unverified quality. It has been our mandate to only offer products using pharmaceutical-grade CBD and to deliver only the best for our customers,” commented Jeff Robinson, CEO of Wuhan.

Manufacturing and Distribution in SA

Our CBD creations are manufactured in South Africa by our subsidiary MJ Medtech. Biodelta Nutraceuticals is our distributor in South Africa and surrounding African countries.

Luka Marjanovic commented as Head of Product for the Company: “I’ve been visiting many of the stores that will be carrying our lines. The in-store specialists are very keen to get our product on the shelf. Customer inquiries about CBD based products in the stores are the talk of the town, without anyone to fill the demand gap – until now. Having boots on the ground and such close relationships with our points of sales are of great value and provide us with vital data. For the launch itself, we will conduct significant campaigning, visiting multiple pharmacies per day and conducting doctor training sessions with the personnel and Dr. Anna.”

Online Sales

The DrAnnaRx™ and Medspresso™ lines will be available for purchase online internationally so long as it respects and complies with the countries’ and states’ laws. Both online shops www.drannarx.com and www.medspresso.store will be open for business in December in time for the Holiday season.

Distribution in Canada

In the coming weeks, Wuhan will be applying to Health Canada for its Processing License under the Cannabis Act to allow the sale of cosmetics, topicals, and edibles for medical and legal adult consumer markets.

The Company plans to submit 5 SKUs to Health Canada and plans on submitting more in the coming months as it expands its product lines.

“We are working very hard to create significant value for our shareholders and are definitely going to take advantage of the recent Canadian regulations that went into effect October 17, 2019,” commented Jeff Robinson, CEO of Wuhan.

Delay

Chief Executive Officer Jeff Robinson took a medical leave of absence, during the last quarter. In his absence, company operations were reduced to a minimum until he was fit and healthy to travel back to Cape Town, South Africa. Wuhan is pleased to say that Jeff is in full recovery and back in South Africa with the Team.

Mushrooms

Wuhan has been researching multiple medicinal mushroom types in order to formulate its upcoming range of cosmetics, coffee, and teas for commercialization in early Q1 of 2020 within its M2Bio division.

“We are very excited about the launch in South Africa. We will be selling our products to our first customers in the coming weeks. It’s a huge milestone for the company and its shareholders,” said Jeff Robinson, CEO of Wuhan.

About Wuhan General Group, Inc.

Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under the Dr. AnnaRx™ and Medspresso™ brands. In addition, its new wholly-owned division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. Wuhan is listed and traded on the Over the Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

Wuhan General Group, Inc.

Publicly traded company (OTC Pink: WUHN)

Website: www.wuhn.org

For further information contact:

Public Relations

E-mail: info@wuhn.org

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

Primary Logo

Posted on

Vireo Health Names Bruce Linton as Executive Chairman

MINNEAPOLIS, Nov. 7, 2019 /PRNewswire/ — Vireo Health International, Inc. (“Vireo” or the “Company”) (CNSX: VREO; OTCQX: VREOF), a leading physician-led, science-focused, multi-state cannabis company, today announced that it has named Bruce Linton to the role of Executive Chairman. As Executive Chairman, Mr. Linton will be actively involved in the Company’s business. He will serve on the board of directors, work closely with Vireo CEO & Founder Kyle Kingsley, M.D., and spearhead the Company’s strategic decision-making, capital markets activity and future partnerships.

Vireo Logo (PRNewsfoto/Vireo Health, Inc.)

“I am delighted to be joining Vireo, one of the most exciting cannabis companies in the United States with an impressive medical and scientific team developing the next generation of cannabis products,” said Bruce Linton. “Beyond the attractive collection of strategic assets and intellectual property that Dr. Kingsley has assembled, I have taken this role because I share the Company’s ambitious vision for the future of cannabis. We are confident Vireo can become a top US producer and distributor of high-margin, proprietary products within the next several years and create unprecedented long-term shareholder value.”

“There is no greater endorsement than Bruce Linton joining as Executive Chairman. Bruce’s extraordinary track record in the cannabis industry speaks for itself and I am incredibly excited about the opportunity to work closely with this industry trailblazer,” said Kyle Kingsley, M.D., CEO & Founder of Vireo. “Furthermore, Bruce lives by our Company’s philosophy, our dedication to our customers and co-workers, and he understands the importance of giving back to the communities in which we operate.”

Mr. Linton is the founder and former CEO of Canopy Growth Corporation (“Canopy Growth”) and co-founder of Tweed Marijuana Incorporated. Under Mr. Linton’s leadership, Canopy Growth was the first cannabis producing company in North America to be listed on a major stock exchange (TSX) and included on a major stock index (S&P/TSX Composite Index).  Canopy Growth was also the first cannabis-producing company to list on the New York Stock Exchange. After beginning his career at Newbridge Networks Corporation, Mr. Linton held positions that include General Manager and Re-Founder of Computerland.ca, President and Co-Founder of webHancer Corp., and part of the establishing team at CrossKeys Systems Corporation (“CrossKeys”). He was also part of the leadership team for the NASDAQ/TSX initial public offering at CrossKeys. He is the past Chairman of the Ottawa Community Loan Foundation, past Board Member and Treasurer of Canada World Youth, past Board of Governor for Carleton University, past President of the Nepean Skating Club, and past President of the Carleton University Students Association.

As Executive Chairman, Mr. Linton will receive incentive-based compensation in the form of three tranches of incentive warrants (the “Incentive Warrants”) to acquire up to 15 million subordinate voting shares in the Company.  The first tranche of 10 million Incentive Warrants has an exercise price of US$1.02, being the closing price of the Company’s subordinate voting shares on November 6, 2019. The second tranche of 2.5 million Incentive Warrants has an exercise price of US$3.81. The third tranche of 2.5 million Incentive Warrants has an exercise price of US$5.86. All three tranches of the Incentive Warrants will expire on November 7, 2024, and vest over two years, with 50% vesting on each of November 6, 2020 and November 6, 2021.

The grant of Incentive Warrants was subject to receipt of disinterested shareholder approval in accordance with the policies of the Canadian Securities Exchange.  Disinterested shareholder approval has been obtained pursuant to a written consent resolution.  Specifically, Dr. Kingsley (director and CEO of Vireo), Amber Shimpa (director and CFO of Vireo), and certain other disinterested Vireo shareholders (the “Disinterested Shareholders”) who, in the aggregate, beneficially own securities of the Company carrying more than 50% of the voting rights of the Company, voted in favour of the grant of the Incentive Warrants.  For the purposes of the written consent resolution, “disinterested shareholder approval” means the approval by shareholders holding at least 50% of the voting control of the Company and excluding any votes of shareholders to whom Incentive Warrants were granted to.  Dr. Kingsley, Ms. Shimpa and the Disinterested Shareholders were the only shareholders included in the written consent resolution and the Incentive Warrants were only granted to Mr. Linton; accordingly, the Company did not need to consider if any votes needed to be excluded from the written consent resolution.

Chad Martinson, who has served on the company’s Board of Directors since March 2019, has resigned from the Board in conjunction with Mr. Linton’s appointment. The company is grateful to Mr. Martinson for his service.

All currency figures referenced in this release reflect U.S. dollar amounts, unless otherwise noted.

About Vireo Health International, Inc.

Vireo Health International, Inc.’s mission is to build the cannabis company of the future by bringing the best of medicine, engineering and science to the cannabis industry.  Vireo’s physician-led team of more than 400 employees provides best-in-class cannabis products and customer experience. Vireo cultivates cannabis in environmentally friendly greenhouses, manufactures pharmaceutical-grade cannabis extracts, and sells its products at both company-owned and third-party dispensaries. The Company currently is licensed in eleven markets including Arizona, Maryland, Massachusetts, Minnesota, New Mexico, New York, Nevada, Ohio, Pennsylvania, Puerto Rico, and Rhode Island.  For more information about the Company, please visit www.vireohealth.com.

Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation.  Statements in this news release that are forward-looking information are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Vireo’s periodic filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, expectation, intend, can, may, potential, believe, should, our vision” and similar expressions, are forward-looking information.

Forward-looking information may include, without limitation, statements including Vireo’s business strategy.

Readers should not place undue reliance on forward-looking information. The forward-looking information in this news release are made as of the date of this release. Vireo disclaims any intention or obligation to update or revise such information, except as required by applicable law, and Vireo does not assume any liability for disclosure relating to any other company mentioned herein.

The Canadian Securities Exchange (“CSE”) has not reviewed and does not accept responsibility for the adequacy of this news release. Neither the CSE nor its “regulation services provider” (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Contact Information:

Investor Inquiries
Sam Gibbons
Vice President, Investor Relations
samgibbons@vireohealth.com
(612) 314-8995

Media Inquiries
Erin Passan
Gagnier Communications
Managing Partner
epassan@gagnierfc.com
949-922-2112

Albe Zakes
Vice President, Corporate Communications
albezakes@vireohealth.com
(267) 221-4800

 

CisionView original content to download multimedia:http://www.prnewswire.com/news-releases/vireo-health-names-bruce-linton-as-executive-chairman-300953902.html

SOURCE Vireo Health International, Inc.

Posted on

Field Trip Psychedelics Inc. Adds Michael Ehlers, Accomplished Neuroscientist and Veteran Pharmaceutical Industry R&D Executive, as Strategic Advisor

TORONTO, Nov. 5, 2019 /PRNewswire/ — Field Trip Psychedelics Inc. (“Field Trip” or the “Company“), the world’s first integrated company in legal psychedelics and psychedelic-assisted psychotherapy, is pleased to announce the appointment of of Dr. Michael Ehlers as a Strategic Advisor to the Company.

“There are few people as uniquely qualified as Dr. Ehlers to help guide the scientific direction for Field Trip, and advance the therapeutic potential of psychedelic medicine,” said Ronan Levy, co-founder of Field Trip. “In addition to his recognized expertise in neuroscience, Mike also brings to Field Trip his accomplished career in senior scientific and business roles with some of the largest and most successful biopharmaceutical companies, along with his experience in academia. As an advisor, he will help us establish our scientific strategy, provide guidance to our growing research and development team, and leverage our research in Jamaica to create value and advance our understanding of the therapeutic and business opportunities in psychedelics.”

Dr. Ehlers has over two decades of academic and business experience in neuroscience and drug development, serving in various senior roles within the biotechnology and pharmaceutical industries. He currently serves as Chief Scientific Officer and Venture Partner at Apple Tree Partners. Prior to Apple Tree, Dr. Ehlers was Executive Vice President and Head of Research & Development at Biogen, a multinational biotechnology company specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.  Before Biogen, Dr. Ehlers served as Group Senior Vice President, Biotherapeutics and Chief Scientific Officer of Neuroscience at Pfizer where he led global research and development in neuroscience, pain and rare disease.

“Nearly 1 in 4 Americans will be diagnosed with a severe mental illness in their lifetime. Depressive disorders are one of the single largest contributors to global disease burden,” said Dr. Ehlers. “Many large pharma companies have stepped away from neuropsychiatric disease.   As a consequence, the pipeline for new drugs is limited. Therapeutic psychedelics are some of the most exciting new approaches being investigated to fight the burgeoning global mental health crisis happening right now.  It is critical that we make smart investments, develop the research rigorously, and advance this industry in a thoughtful way. I am excited to be helping Field Trip do just that.”

Before entering the private sector, Dr. Ehlers spent 12 years as Howard Hughes Medical Institute Investigator and George Barth Geller Professor of Neurobiology at Duke University.  He holds M.D. and Ph.D. degrees from the Johns Hopkins University School of Medicine, one of the leading research institutions investigating the potential therapeutic benefits of psychedelics.

About Field Trip Psychedelics, Inc.
Field Trip is the world’s first integrated company in legal psychedelics. With current and planned operations in North America, the Caribbean and Europe, Field Trip’s goal is to become the recognized global leader in the medical and therapeutic applications of psychedelics.
Learn more at https://fieldtriphealth.com

SOURCE Field Trip Psychedelics Inc.

Related Links

https://fieldtriphealth.com

Posted on

Vireo Health Launches New ‘Green Goods’ Retail Dispensary Brand in Scranton, Pennsylvania

MINNEAPOLIS, Oct. 30, 2019 /PRNewswire/ — Vireo Health International, Inc., (“Vireo” or the “Company”) (CSNX: VREO; OTQX: VREOF), a leading physician-founded, science-focused multi-state cannabis company, today announced the launch of its new and innovative Green Goods™ retail dispensary brand.

Logo of Green Goods the new dispensary brand from Vireo Health, a physician-founded, science-focused cannabis company.

The first Green Goods branded retail location opened today in Scranton, Pennsylvania offering customers cannabis products from Vireo and other state-licensed manufacturers. The Company plans to open a second Green Goods location in Bethlehem, Pennsylvania and a third location in Stroudsburg, Pennsylvania, pending regulatory approval. The Company intends on launching all new dispensaries and renovating existing ones under the Green Goods banner.

“Green Goods represents the next evolution of Vireo’s commitment to providing a best-in-class personalized customer experience,” said Kyle Kingsley, M.D. Founder and CEO of Vireo. “The design of Green Goods provides a safe, welcoming environment for all customers featuring on-site pharmacists and a ‘knowledge bar’ for those interested in learning more about cannabis.”

The Green Goods experience will extend to the community at-large and to the digital sphere. Building on the Company’s commitment to social responsibility, Green Goods dispensaries will serve as a hub for community programs, educational events, and advocacy. Moreover, a new eCommerce platform will soon be launched to compliment the in-store experience by offering convenient pick up and home delivery options, where permitted by regulations.

“The Green Goods brand represents Vireo’s dedication to patients, plant-based medicine, and the planet,” said Harris Rabin, Chief Marketing Officer of Vireo. “Cannabis offers customers a more natural alternative and so we created Green Goods to embody that connection to the nature and transform how we interact with our patients, communities, and employees.”

The innovative layout and modern aesthetics of the Green Goods stores were created by Tersigni Palachek, a leading New York-based design firm. The Green Goods brand strategy and identity were developed in partnership with AP Keaton, a New York-based brand agency.

About Vireo Health International, Inc.
Vireo Health International, Inc.’s mission is to build the cannabis company of the future by bringing the best of medicine, engineering and science to the cannabis industry.  Vireo’s physician-led team of nearly 400 employees provides best-in-class cannabis products and customer experience. Vireo cultivates cannabis in environmentally friendly greenhouses, manufactures pharmaceutical-grade cannabis extracts, and sells its products at both company-owned and third-party dispensaries. The Company currently is licensed in eleven markets including Arizona, Maryland, Massachusetts, Minnesota, New Mexico, New York, Ohio, Pennsylvania, Puerto Rico, and Rhode Island.  For more information about the Company, please visit www.vireohealth.com.

Contact Information

Media Inquiries
Albe Zakes
Vice President, Corporate Communications
albezakes@vireohealth.com
(267) 221-4800

Investor Inquiries
Sam Gibbons
Vice President, Investor Relations
samgibbons@vireohealth.com
(612) 314-8995

 

CisionView original content to download multimedia:http://www.prnewswire.com/news-releases/vireo-health-launches-new-green-goods-retail-dispensary-brand-in-scranton-pennsylvania-300947888.html

SOURCE Vireo Health International, Inc.

Posted on

AbbVie’s Suzanne Campbell recognized by peers

Montreal, Quebec, October 23, 2019 – AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, announced today that Suzanne Campbell, Senior Brand Manager, Dermatology was inducted into the Canadian Healthcare Marketing Hall of Fame.

 

The Canadian Healthcare Marketing Hall of Fame awards were established to honor healthcare marketers who have contributed to the industry avocation and are an inspiration to others.

 

Suzanne Campbell credits her success to the team around her, which encompasses a motto that has governed her career—Together Everyone Achieves More (TEAM). “I constantly see that any idea or strategy gets so much better when you have the brain power of multiple colleagues and multiple perspectives,” said Campbell. “And that collaboration makes any project more robust.”

 

Suzanne was recognized for her work in hidradentis suppurativa (HS). HS is a painful, chronic, systemic, immune-mediated skin disease which affects between 1 to 3% of the global population however the diagnosis is often delayed or the condition is misdiagnosed with the true prevalence unknown.1 HS is known to produce lesions in the skin that are inflamed (swollen), recurrent and chronic (lasting for an extended period of time). HS can have both a psychological and physical impact.

 

“When I started meeting people with HS, their patient journey, which had been a very negative one in the healthcare system, became my passion project.”

 

Stéphane Lassignardie, President, AbbVie Canada added: “We are very proud of Suzanne for this important acknowledgement. It is testament of our industry recognizing the importance of finding solutions for patients’ where there are no options and real medical need for solutions.”

 

About AbbVie

AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie

 

 

 

 

 

 

 

 

employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.ca and www.abbvie.com. Follow @abbvieCanada and @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

 

 

Media:

Eileen Murphy AbbVie Canada (514) 832-7788

eileen.murphy@abbvie.com

 

 

###

 

1 The Canadian Hidradenitis Suppurativa Foundation – www.hs-foundationcanada.org

Posted on

Spherix Issues Update to Shareholders

NEW YORK, Oct. 21, 2019 /PRNewswire/ — Spherix Incorporated (Nasdaq: SPEX) President and CEO, Anthony Hayes, today released a letter to shareholders outlining the Company’s plans for its previously disclosed dividend distribution.

Spherix Logo. (PRNewsFoto/Spherix Incorporated)

Dear Fellow Shareholder,

As we accelerate our transformation into an innovative biotech company, I believe this is the optimal time to provide our shareholders with a detailed update.  I am excited at the potential for Spherix and believe we have put several important pieces in place to drive future success.

First, October 21, 2019 is the record date for our dividend distribution.  If you are a shareholder of record at 5 p.m. Eastern Standard on that date, you will receive one share of Hoth Therapeutics, Inc common stock for every 29 shares of Spherix common stock you own.  The distribution of the Hoth shares is currently anticipated to occur on or about October 28, 2019, subject to effectiveness of the registration statement for such shares. Spherix will not distribute fractional shares of Hoth common stock, and any fractional shares will be rounded down to the nearest whole share.

Aside from the valuable assets already owned by Spherix, it is time to look forward and build on the successful investment in Hoth.  Upon the closing of the asset acquisition from CBM BioPharma, Inc. (CBM), Spherix will acquire anticancer drugs that provide shareholders access to billion-dollar oncology markets.  For example, the global acute myeloid leukemia (AML) market is expected to reach $2.2 billion by 2025 growing at CAGR 19.6% over the forecast period.

Beyond the big picture, the CBM assets provide shareholders and investors with comparable drugs to help establish value in these growing markets.  For example, KPC34 treats acute myeloid leukemia and has shown tremendous promise in treating relapsed/refractory AML cancer that has a certain type of mutation.  Tibsovo®, by Agios Pharmaceuticals, Inc., also treats relapsed/refractory AML that has a certain mutation of the disease.  In July of 2018, the FDA approved Tibsovo (ivosidenib) for Relapsed or Refractory Acute Myeloid Leukemia with an IDH1 Mutation after a 177-person, Phase 1 study.  According to results published by Agios, Tibsovo generated $13.7 million in revenue for the second quarter of 2019 and they expect that to grow.  A terrific result, when you look at the approval timeline for the drug:

  • Dec 26, 2017: Agios Pharmaceuticals submits new drug application to the FDA for Ivosidenib for the treatment of patients with relapsed/refractory AML and an IDH1 Mutation.
  • Feb 15, 2018: FDA accepts new drug application and grants priority review for Ivosidenib in relapsed or refractory AML with an IDH1 Mutation.
  • Jul 20, 2018: FDA Approves Tibsovo (ivosidenib) for relapsed or refractory Acute Myeloid Leukemia with an IDH1 Mutation.

Tibsovo is one of three similar AML drugs that have received FDA Orphan Drug status and Fast Track designation for the treatment of AML, as well as priority review.  The other two drugs are IDHIFA® (enasidenib) by Celgene Corporation and XOSPATA® (gilteritinib) by Astellas Pharma US.

Astellas had a similar approval timeline and revenue results, reporting sales of around $22 million for Xospata in the first quarter of fiscal 2019, and has said it expects that to increase to around $140 million for the full year, with an FDA approval timeline of:

  • Apr 23, 2018 Astellas Submits New Drug Applications for Approval of Gilteritinib for the Treatment of FLT3mut+ Relapsed or Refractory Acute Myeloid Leukemia.
  • May 29, 2018 U.S. FDA Grants Priority Review to Astellas’ New Drug Application for Gilteritinib for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML).
  • Nov 28, 2018 Approval FDA Approves Xospata (gilteritinib) for Acute Myeloid Leukemia (AML) with a FLT3 Mutation.

The AML cancer mutation treated by KPC34 is different than the mutations treated by the drugs referenced above, but these examples show quantitative comparable for KPC34. Spherix cannot guarantee a similar result, but we have been working closely with CBM and Wake Forest University to move KPC34 forward on a similar regulatory approval process.

We understand that timelines and milestones are important.  We project to have the CBM transaction closed before the end of November, subject to the satisfaction of certain closing conditions.  Thereafter, we intend to continue work on the clinical trial protocol and finish the Orphan Drug application, both of which already have a working draft completed.

As you can see, the opportunities in front of us are significant, and the pathway to value creation, based on comparable companies, is well-established.  I trust you share our excitement. We look forward to bringing you additional updates as they materialize.

Thank you for your continued support.

Sincerely,

Anthony Hayes

About Spherix
Spherix Incorporated was launched in 1967 as a scientific research company. Spherix is committed to advancing innovation by active participation in the patent market. Spherix draws on portfolios of pioneering technology patents to partner with and support product innovation.

Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the Securities and Exchange Commission (the “SEC”), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact: 

Investor Relations:   

Hayden IR

Brett Mass, Managing Partner

Phone: (646) 536-7331

Email: brett@haydenir.com

www.haydenir.com

Spherix:                  

Phone: 212-745-1373

Email: investorrelations@spherix.com

www.spherix.com

 

CisionView original content to download multimedia:http://www.prnewswire.com/news-releases/spherix-issues-update-to-shareholders-300941469.html

SOURCE Spherix Incorporated

News Provided by PR Newswire via QuoteMedia